We are live on ! Find out more
CLSD

Clearside Biomedical

Delisted

CLSD was delisted on the 28th of November, 2025.

54 hedge funds and large institutions have $9.62M invested in Clearside Biomedical in 2023 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 10 increasing their positions, 13 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 5

16% more call options, than puts

Call options by funds: $136K | Put options by funds: $117K

8% more funds holding

Funds holding: 5054 (+4)

6% more capital invested

Capital invested by funds: $9.09M → $9.62M (+$532K)

0.02% less ownership

Funds ownership: 0.95%0.93% (-0.02%)

23% less repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 13

Holders
54
Holders Change
+4
Holders Change %
+8%
% of All Funds
0.85%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
10
Increased
10
Reduced
13
Closed
5
Calls
$136K
Puts
$117K
Net Calls
+$19K
Net Calls Change
-$32K

CLSD Hedge Fund Activity: Q2 2023 in Review

54 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Clearside Biomedical (CLSD) for Q2 2023, worth a combined $9.62M — up 5.9% from $9.09M a quarter earlier.

Buyers outnumbered sellers: 10 funds opened new CLSD positions and 5 closed out — a net gain of 5 holders — while 10 added to existing stakes and 13 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $139K. The largest seller was Renaissance Technologies, cutting an estimated $141K.

  • 54 institutional investors held Clearside Biomedical (CLSD) as of Q2 2023, up from 50 in Q1 2023.
  • Funds reported $9.62M of Clearside Biomedical stock for Q2 2023, up 5.9% quarter-over-quarter.
  • 10 funds opened new Clearside Biomedical positions in Q2 2023 and 5 closed out, a net change of +5 holders.
  • The largest Clearside Biomedical buyer in Q2 2023 was Morgan Stanley, an estimated $139K added.
  • The largest Clearside Biomedical seller in Q2 2023 was Renaissance Technologies, an estimated $141K sold.

Based on aggregated 13F filings for Q2 2023.